Tetrabenazine augmentation in treatment-resistant schizophrenia: A 12-week, double-blind, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 95-99

  Remington, Gary ^a,b   Kapur, Shitij ^c   Foussias, George ^a,b   Agid, Ofer ^a,b   Mann, Steve ^b   Borlido, Carol ^b   Richards, Sandy ^b   Javaid, Naima ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

augmentation; tetrabenazine; treatment resistant schizophrenia; VMAT2

Indexed keywords

CLOZAPINE; DOPAMINE; PLACEBO; TETRABENAZINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; ASTHENIA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; HUMAN; INSOMNIA; LASSITUDE; MALE; NERVOUSNESS; PARKINSONISM; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SLEEP; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TETRABENAZINE;

EID: 84855359729     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823f913e     Document Type: Article

References (28)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
3. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443-457.
4. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25:383-399.
5. Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10:2883-2896.
6. Gonzalez AM,Walther D, Pazos A, et al. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994;22:219-226. (Pubitemid 24063643)
7. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol. 1982;12:257-262. (Pubitemid 12053032)
8. Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983;225:515-521. (Pubitemid 13070863)
9. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193-197. (Pubitemid 46374760)
10. Healy DJ, Dalack GW, Meador-Woodruff JH. Clozapine-reserpine combination for refractory psychosis. Schizophr Res. 1997;25:259-260. (Pubitemid 27323836)
11. Lingjaerde O. Tetrabenazine. Acta Psychiatr Scand. 1963;38(suppl 170):1-109.
12. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717-719.
13. First M. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1997.
14. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898-911. (Pubitemid 34020701)
15. Guy W. Assessment Manual for Psychopharmacology. Rockville,MD: National Institute of Mental Health; 1976.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
17. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties (CPS). Ottawa, Canada: CPA; 2010.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
19. Simpson GM, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212:S27-S34.
20. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334(suppl):1-100.
21. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251. (Pubitemid 20228720)
22. Longenecker J, Genderson J, Dickinson D, et al. Where have all the women gone? Participant gender in epidemiological and non-epidemiological research of schizophrenia. Schizophr Res. 2010;119:240-245.
23. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358-362. (Pubitemid 27087603)
24. Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008;23:435-437. (Pubitemid 351460709)
25. Remington G. Augmenting clozapine response in treatment-resistant schizophrenia. In: Elkis H, Meltzer, HY, ed. Therapy-Resistant Schizophrenia. Basel, Switzerland: Karger; 2010:129-151.
26. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev. 2000;31: 371-384. (Pubitemid 30136193)
27. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997;17:205-229. (Pubitemid 27440642)
28. Lyon GJ, Abi-Dargham A, Moore H, et al. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull. 2011;37:108-117.